|
About the Regulatory & Compendial category
|
|
0
|
18
|
August 13, 2026
|
|
ICH M7 & Nitrosamines Impurities -Updates
|
|
21
|
6010
|
November 3, 2026
|
|
US FDA on LTL adjustments for Nitrosamines
|
|
34
|
2028
|
November 3, 2026
|
|
EMA/ CMDh meeting - Sept 2026 - BE requirements following formulation changes
|
|
0
|
155
|
October 21, 2026
|
|
๐ฏ๐ต Recommendations by Japanese Society of Generic and Biosimilar Medicines
|
|
0
|
94
|
October 16, 2026
|
|
๐ธ๐ฆ Saudi FDA requesting Nitrosamines Risk Assessments
|
|
6
|
2113
|
October 13, 2026
|
|
๐จโ๐ป Dashboard Containing Published AI Limits
|
|
33
|
4774
|
September 8, 2026
|
|
The TGA updated information for acceptable intake of nitrosamine impurities in medicines on 14 August 2026
|
|
0
|
544
|
August 14, 2026
|
|
๐บ๐ธ FDA updates 'estimated duration' dates on Recommended Interim AI limits
|
|
1
|
308
|
August 3, 2026
|
|
N-Nitroso Abacavir Impurity possibility in physical state as standard
|
|
5
|
212
|
August 1, 2026
|
|
Requirements for NAs assessment in Russia
|
|
8
|
529
|
July 10, 2026
|
|
Indian Pharmacopoeia introduces a new General Chapter on Nitrosamine Impurities in its 2022 edition
|
|
4
|
2121
|
June 26, 2026
|
|
Mutagenic Impurities in USP -future looking
|
|
17
|
1849
|
June 26, 2026
|
|
Regulatory Flexibilities and Clarifications: Chemistry, Manufacturing and Control (CMC) Information for Original First in Human (FIH) Phase 1 INDs
|
|
2
|
432
|
June 25, 2026
|
|
Upcoming EMA Q&A for other nitrosocompounds
|
|
3
|
540
|
June 5, 2026
|
|
An updated version of Health Canada's Guidance on nitrosamine impurities in medications(Update May 29, 2026)
|
|
0
|
392
|
June 2, 2026
|
|
Analysis of Nitrite in Pharmaceutical Excipients: A MultiโLaboratory Comparative Study - PUB
|
|
3
|
555
|
June 1, 2026
|
|
๐ฐ๐ท MFDS Guideline: Compilation of Analysis Methods on the Determination of Impurities in Pharmaceuticals, May-2026
|
|
2
|
387
|
May 19, 2026
|
|
N-Nitroso Mefanaminc Acid
|
|
1
|
175
|
May 12, 2026
|
|
N-Nitroso dially amine estimation by LCMS
|
|
2
|
120
|
April 29, 2026
|
|
Nitrosamine limit in the specification based on intermediate and accelerated stability condition results
|
|
4
|
313
|
April 28, 2026
|
|
๐ธ๐ฌ Singapore formalized Nitrosamine requirements for NDA and GDA Applications
|
|
0
|
182
|
April 1, 2026
|
|
๐ฒ๐ฝ Mexico Nitrosamine Guide published today
|
|
46
|
4400
|
January 16, 2026
|
|
Nitrosamine impurity evaluation in animal health API
|
|
1
|
171
|
January 15, 2026
|
|
Evaluation of Nitrosamine impurities in animal health APIs
|
|
1
|
176
|
January 8, 2026
|
|
Liquid medicinal product with lidocaine
|
|
4
|
257
|
January 8, 2026
|
|
Nitrosamine impurities in animal health APIs
|
|
1
|
263
|
December 24, 2025
|
|
Establishing Best Practice for N- Nitrosamine Read-Across and Surrogate Selection
|
|
0
|
202
|
December 22, 2025
|
|
๐ช๐ฌ Egypt (EDA) Public Consultation regarding the Guidelines for Nitrosamine Impurities
|
|
0
|
142
|
November 19, 2025
|
|
EMA - nitrosamines Leading Member State (LMS)
|
|
2
|
392
|
November 13, 2025
|